DRR168590
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.450
- ANGIOGENESIS+0.340
- NOTCH_SIGNALING+0.320
- APICAL_JUNCTION+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- HYPOXIA+0.280
- P53_PATHWAY+0.280
- MYOGENESIS+0.260
- UV_RESPONSE_DN+0.260
- PI3K_AKT_MTOR_SIGNALING+0.250
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.350
- MYC_TARGETS_V1-0.330
- OXIDATIVE_PHOSPHORYLATION-0.290
- MYC_TARGETS_V2-0.230
- SPERMATOGENESIS-0.200
- KRAS_SIGNALING_DN-0.190
- INFLAMMATORY_RESPONSE-0.160
- INTERFERON_GAMMA_RESPONSE-0.150
- INTERFERON_ALPHA_RESPONSE-0.120
- PANCREAS_BETA_CELLS-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A18J-01A-11R-A12D-07 | — | C | 0.765 |
| 2 | TCGA-B6-A0RI-01A-11R-A056-07 | — | B | 0.756 |
| 3 | MNG471 | — | — | 0.747 |
| 4 | TCGA-77-8145-01A-11R-2247-07 | — | cohortSQ1 | 0.737 |
| 5 | MNG1012 | — | — | 0.730 |
| 6 | TCGA-77-8146-01A-11R-2247-07 | — | cohortSQ1 | 0.727 |
| 7 | TCGA-85-A50M-01A-21R-A262-07 | — | cohortSQ1 | 0.723 |
| 8 | R211 | — | — | 0.713 |
| 9 | TCGA-CV-5979-01A-11R-1686-07 | — | — | 0.708 |
| 10 | TCGA-CR-7365-01A-11R-2016-07 | — | — | 0.702 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |